336 related articles for article (PubMed ID: 34057709)
1. The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies.
Toll L; Cippitelli A; Ozawa A
CNS Drugs; 2021 Jun; 35(6):591-607. PubMed ID: 34057709
[TBL] [Abstract][Full Text] [Related]
2. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
3. The use of bifunctional NOP/mu and NOP receptor selective compounds for the treatment of pain, drug abuse, and psychiatric disorders.
Toll L
Curr Pharm Des; 2013; 19(42):7451-60. PubMed ID: 23448477
[TBL] [Abstract][Full Text] [Related]
4. Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.
Toll L; Bruchas MR; Calo' G; Cox BM; Zaveri NT
Pharmacol Rev; 2016 Apr; 68(2):419-57. PubMed ID: 26956246
[TBL] [Abstract][Full Text] [Related]
5. Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ.
Donica CL; Awwad HO; Thakker DR; Standifer KM
Mol Pharmacol; 2013 May; 83(5):907-18. PubMed ID: 23395957
[TBL] [Abstract][Full Text] [Related]
6. Role of Nociceptin/Orphanin FQ-NOP Receptor System in the Regulation of Stress-Related Disorders.
Ubaldi M; Cannella N; Borruto AM; Petrella M; Micioni Di Bonaventura MV; Soverchia L; Stopponi S; Weiss F; Cifani C; Ciccocioppo R
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884757
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of nociceptin/orphanin FQ receptors, a novel opioid receptor family, in the midbrain periaqueductal gray.
Chiou LC; Fan SH; Chuang KC; Liao YY; Lee SZ
Ann N Y Acad Sci; 2004 Oct; 1025():398-403. PubMed ID: 15542742
[TBL] [Abstract][Full Text] [Related]
8. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications.
Chiou LC; Liao YY; Fan PC; Kuo PH; Wang CH; Riemer C; Prinssen EP
Curr Drug Targets; 2007 Jan; 8(1):117-35. PubMed ID: 17266536
[TBL] [Abstract][Full Text] [Related]
9. Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder.
Zhang Y; Simpson-Durand CD; Standifer KM
Br J Pharmacol; 2015 Jan; 172(2):571-82. PubMed ID: 24666365
[TBL] [Abstract][Full Text] [Related]
10. Quantitative study of [Tyr10]nociceptin/orphanin FQ (1-11) at NOP receptors in rat periaqueductal gray and expressed NOP receptors in HEK293 cells.
Liao YY; Lee CW; Ho IK; Chiou LC
Life Sci; 2012 Feb; 90(7-8):306-12. PubMed ID: 22213115
[TBL] [Abstract][Full Text] [Related]
11. Nociceptin/orphanin FQ receptor expression in clinical pain disorders and functional effects in cultured neurons.
Anand P; Yiangou Y; Anand U; Mukerji G; Sinisi M; Fox M; McQuillan A; Quick T; Korchev YE; Hein P
Pain; 2016 Sep; 157(9):1960-1969. PubMed ID: 27127846
[TBL] [Abstract][Full Text] [Related]
12. NOP Ligands for the Treatment of Anxiety and Mood Disorders.
Gavioli EC; Holanda VAD; Ruzza C
Handb Exp Pharmacol; 2019; 254():233-257. PubMed ID: 30535941
[TBL] [Abstract][Full Text] [Related]
13. Potential of Nociceptin/Orphanin FQ Peptide Analogs for Drug Development.
Wtorek K; Janecka A
Chem Biodivers; 2021 Jan; 18(1):e2000871. PubMed ID: 33351271
[TBL] [Abstract][Full Text] [Related]
14. Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs.
Gavioli EC; Calo' G
Pharmacol Ther; 2013 Oct; 140(1):10-25. PubMed ID: 23711793
[TBL] [Abstract][Full Text] [Related]
15. Nociceptin/orphanin FQ-NOP receptor system in inflammatory and immune-mediated diseases.
Gavioli EC; de Medeiros IU; Monteiro MC; Calo G; Romão PR
Vitam Horm; 2015; 97():241-66. PubMed ID: 25677775
[TBL] [Abstract][Full Text] [Related]
16. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor.
Calo G; Guerrini R; Rizzi A; Salvadori S; Burmeister M; Kapusta DR; Lambert DG; Regoli D
CNS Drug Rev; 2005; 11(2):97-112. PubMed ID: 16007234
[TBL] [Abstract][Full Text] [Related]
17. Central N/OFQ-NOP Receptor System in Pain Modulation.
Kiguchi N; Ding H; Ko MC
Adv Pharmacol; 2016; 75():217-43. PubMed ID: 26920014
[TBL] [Abstract][Full Text] [Related]
18. Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy?
Zeilhofer HU; Calò G
J Pharmacol Exp Ther; 2003 Aug; 306(2):423-9. PubMed ID: 12721334
[TBL] [Abstract][Full Text] [Related]
19. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
Calo G; Rizzi A; Rizzi D; Bigoni R; Guerrini R; Marzola G; Marti M; McDonald J; Morari M; Lambert DG; Salvadori S; Regoli D
Br J Pharmacol; 2002 May; 136(2):303-11. PubMed ID: 12010780
[TBL] [Abstract][Full Text] [Related]
20. Nociceptin/orphanin FQ receptor and pain: Feasibility of the fourth opioid family member.
Di Cesare Mannelli L; Micheli L; Ghelardini C
Eur J Pharmacol; 2015 Nov; 766():151-4. PubMed ID: 26277324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
